Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Syndax Pharmaceuticals Undervalued On Coming Data Readouts

2018-02-15 seekingalpha
Syndax came up in a screening I did of the new additions to the Nasdaq Biotechnology Index, which is used as a basis for the iShares Nasdaq Biotechnology ETF (IBB). If you want to pick individual stocks and try to beat the IBB, the understanding the component companies is a good place to start. (5-0)

Reata Pharmaceuticals A Buy On Bardoxolene Data

2018-02-14 seekingalpha
Reata Pharmaceuticals (RETA) is a clinical-stage biotechnology company specializing in drugs that affect mitochondria-related diseases. Its lead candidate is for PAH (pulmonary arterial hypertension) resulting from connective tissue disease. (10-0)

ROTY Edition 1 Volume 78: Simplify Your Decision-Making And Stick To Guidelines

2018-02-13 seekingalpha
As always, readers are encouraged to do their own due diligence, manage risk appropriately, and avoid blindly following. (313-2)

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

2018-02-09 seekingalpha
Recent market volatility is addressed and we discuss in depth how to react while sticking to one´s plan. (192-1)

ROTY Edition 1 Volume 76: How To Deal With Market Selloffs And Spring Cleaning For The Contenders List

2018-02-06 seekingalpha
Readers are encouraged to make their voices heard in my recent blog post if they haven´t already. (647-3)

ROTY Edition 1 Volume 75: The Future Of ROTY, Cascadian Acquired And Updates

2018-02-02 seekingalpha
I encourage readers to check out my recent blog post which goes into detail regarding changes to Seeking Alpha and consequently to ROTY. (539-1)

BioSci Rounds Report For Feb. 1, 2018

2018-02-02 seekingalpha
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise. - The Former Fidelity-Magellan Manager (Peter Lynch) (89-0)

miRagen Therapeutics Expands Board of Directors with Appointment of Arlene Morris

BOULDER, Colo., Jan. 05, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that it has appointed biotechnology industry veteran Arlene Morris to the role of independent board member on its Board of Directors, effective January 3, 2018. Ms. Morris has extensive experience in the pharmaceutical and biotechnology industries serving in numerous executive management and board roles. (70-1)

ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades

2018-01-30 seekingalpha
So far feedback has been positive for new features added, namely the position explanation section and updated model account snapshot. (330-0)

U.S. IPO Weekly Recap: PagSeguro Pops And Biotechs Surge As Activity Picks Up

2018-01-27 seekingalpha
Headlined by a $2.3 billion offering from Brazilian payments processor PagSeguro, eight companies raised a combined $3.6 billion this week. PagSeguro's 36% first day pop cemented it as one of the best billion-dollar IPO debuts of the decade. Not to be outdone, biotechs continued to be the hottest sector of the IPO market: the sector's five deals averaged a 39% return. Two LBOs also came public to moderate receptions: Blackstone's Gates Industrial fell slightly in its debut while Apollo-backed slot machine company PlayAGS posted a double-digit gain. (154-0)

2 Small Biotechs With Substantial Upside Potential

2018-01-26 seekingalpha
The biotech sector is perking up this week on the back of two big acquisitions and improved sentiment on the space. (26-1)

ROTY Edition 1 Volume 73: New Features And A Controversial Swap Out

2018-01-25 seekingalpha
We are swapping out a current holding for a recent addition to the Contenders List (please read full write-up and be aware of risks). (158-4)

Syndax Pharmaceuticals Is In For A Potentially Transformative 2018

2018-01-25 seekingalpha
Shares of Syndax Pharmaceuticals (SNDX) have lost a quarter of their value since my initial write-up, far from the run-up that I was expecting in 2017. The stock had fallen off my radar, but thankfully as is often the case, a reader brought it back to my attention. (230-0)

3 Top-Ranked Drug Stocks That Are Broker Favorites

2018-01-18 investorplace
Pharma and biotech stocks made an impressive comeback in 2017 with the Nasdaq Biotechnology Index and the NYSE ARCA Pharmaceutical Index gaining 18.7% and 11.8%, respectively. Investors appear to be more comfortable about the drug pricing scenario which was a major overhang in 2016. (85-2)

4 of the Best Stocks to Buy on Earnings Acceleration

2018-01-18 investorplace
Since we are in the thick of the earnings season, investors should look for stocks that are ready to make a big move. Upbeat earnings results are more often than not followed by an uptick in the share price. Take a company’s revenues over a given period of time, subtract the cost of production and you will have its earnings! (11-0)

CUSIP: 87164F105